Información del producto
Nombre:
Tafamidis meglumine
Sinónimos:
- Vyndaqel
- Fx 1006A
- D-Glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Descripción:
Tafamidis meglumine is a drug that belongs to the class of drugs for treating cardiomyopathy. It is a prodrug of tafamidis which is hydrolyzed in vivo to its active form, tafamidis meglumine. Tafamidis meglumine has long-term efficacy and prevents the progression of heart failure by inhibiting the development of cardiac hypertrophy. This drug also has been shown to be effective against brain natriuretic peptides and other symptoms such as edema, anemia, and renal dysfunction. Tafamidis meglumine inhibits the activity of protein phosphatase 2A (PP2A), which dephosphorylates cardiac troponin I at serine residue 222. This leads to increased levels of troponin I, which induces apoptosis in cardiomyocytes.
Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:
Propiedades químicas
Peso molecular:
503.33 g/mol
Fórmula:
C21H24Cl2N2O8
Pureza:
Min. 95%
MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:
